CVS Health Corporation $CVS Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management more than doubled its CVS Health position in the second quarter, acquiring 899,942 additional shares and ending with a stake worth approximately $183.8 million. Institutional investors collectively own 80.66% of the company.
• CVS reported adjusted earnings of $2.58 per share and revenue of $106.1 billion, beating estimates, while raising full-year 2026 adjusted EPS guidance to $7.90–$8.10. The outlook was supported by improving Aetna performance, stronger drug revenue and a more profitable pharmacy mix.
• Despite the positive results and a “Moderate Buy” analyst consensus, investors remain concerned about potential 2027 pressure on Caremark from 340B program changes and declining membership. CVS also expanded its weight-management strategy through a collaboration with Eli Lilly to offer Zepbound and other GLP-1 treatments.

Assenagon Asset Management S.A. increased its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 102.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,776,295 shares of the pharmacy operator's stock after acquiring an additional 899,942 shares during the period. Assenagon Asset Management S.A. owned approximately 0.14% of CVS Health worth $183,758,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in CVS. Swiss RE Ltd. bought a new stake in shares of CVS Health in the 4th quarter worth approximately $26,000. Sankala Group LLC bought a new stake in CVS Health during the fourth quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its position in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after buying an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health in the fourth quarter valued at $28,000. Finally, Ares Financial Consulting LLC bought a new position in shares of CVS Health in the fourth quarter valued at $29,000. Institutional investors own 80.66% of the company's stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. All three major segments—Aetna insurance, pharmacy services and health services—contributed to the result. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and increased operating cash-flow guidance to at least $11.5 billion. Improved medical-cost performance at Aetna, stronger drug revenue and a more profitable pharmacy mix supported the outlook. CVS Health reports strong second-quarter results and raises full-year guidance
• Positive Sentiment: CVS also expanded its weight-management strategy through a collaboration with Eli Lilly, offering additional access to Zepbound and other GLP-1 treatments through CVS Pharmacy and its digital care platform. The initiative could support pharmacy traffic and future growth. CVS Health enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: The improving Aetna Medicare Advantage business is a key turnaround catalyst, but management’s commentary suggests the recovery is still being evaluated against changing healthcare costs and reimbursement conditions. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks
• Negative Sentiment: Investors remain concerned about 2027 pressure on Caremark from potential 340B program changes and declining membership. Those risks could offset current insurance improvements and help explain why the stock fell despite the earnings beat and higher 2026 outlook. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CVS shares. DA Davidson raised their price objective on CVS Health from $80.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Wells Fargo & Company boosted their target price on CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Argus upped their target price on CVS Health from $90.00 to $104.00 and gave the company a "buy" rating in a report on Thursday, May 14th. Barclays lifted their price target on CVS Health from $106.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, TD Cowen upped their price objective on shares of CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, May 11th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus price target of $106.46.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company's stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 3,372,000 shares of company stock valued at $317,473,598. 0.85% of the stock is owned by corporate insiders.

CVS Health Price Performance

CVS opened at $96.32 on Friday. The stock has a fifty day moving average of $102.17 and a 200-day moving average of $87.68. The firm has a market capitalization of $122.90 billion, a P/E ratio of 25.48, a PEG ratio of 0.90 and a beta of 0.61. CVS Health Corporation has a 12-month low of $62.55 and a 12-month high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health's revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts forecast that CVS Health Corporation will post 8 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's payout ratio is 70.37%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source